Dabigatran compound and preparation method and medicinal composition thereof
A technology of dabigatran etexilate and dabigatran etexilate mesylate, which is applied in the field of medicine, can solve the problems of many interfering factors, large individual differences in dosage, and narrow treatment window, and achieve easy operation, few types of use, Conducive to the effect of production and storage
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Example Embodiment
[0031] Example 1: Preparation of dabigatran etexilate mesylate:
[0032] Dissolve 6.278g (0.01mol) of dabigatran etexilate (as described in WO 98 / 37075) in 400ml ethyl acetate, add 0.961g (0.01mol) methanesulfonic acid dissolved in acetic acid at room temperature while stirring 40ml of ethyl ester solution, after the addition, continue to stir for 60 minutes, then place in an ice bath and stir for another 40 minutes, filter, wash the filter cake with 80ml ethyl acetate, and dry in a circulating air dryer at 55°C for 3 hours to obtain 6.85g Bigatran etexilate methanesulfonate anhydrate, the yield is 94.6%. Melting point: 178-179°C.
[0033] Elemental analysis:
[0034] Elemental analysis Actual value% Theoretical value% C58.0258.09 H6.326.22 N13.6013.55 O17.2417.27 S4.474.43
Example Embodiment
[0035] . [0027] Example 2: Preparation of the dabigatran etexilate compound of the present invention:
[0036] Take 2g of dabigatran etexilate mesylate in Example 1, add 100ml of 60℃ hot water to dissolve, cool to 15~20℃ and stir for 1 hour, then cool to 5~10℃ and stir for 1 hour, and finally cool to -5 After stirring for 10 hours at -0°C, crystals were precipitated, filtered, and the filter cake was dried at 35°C and 65% relative humidity for 6 hours to obtain 1.68g of the dabigatran etexilate compound of the present invention with a yield of 82%.
[0037] Elemental analysis:
[0038] Elemental analysis Actual value% Theoretical value% C56.5656.68 H6.386.34 N13.2513.22 O19.4619.43 S4.274.32
[0039] The water content in the dabigatran etexilate compound of the present invention measured by Karl Fischer method is 2.2% (theory: 2.4%); the result of thermogravimetric analysis shows that it is a monohydrate.
Example Embodiment
[0040] Example 3: Preparation of the dabigatran etexilate compound of the present invention:
[0041] Take 2g of dabigatran etexilate methanesulfonate in Example 1, add 100ml of 60°C hot water to dissolve, cool to 15-20°C and stir for 1 hour, then cool to 5-10°C and stir for 1 hour, and finally cool to- Stir at 5-0°C for 10 hours to precipitate crystals, filter, and dry the filter cake at 30°C and 60% relative humidity for 8 hours to obtain 1.63 g of the dabigatran etexilate compound of the present invention with a yield of 80%.
[0042] Elemental analysis:
[0043] Elemental analysis Actual value% Theoretical value% C56.6156.68 H6.296.34 N13.2813.22 O19.5119.43 S4.264.32
[0044] The water content in the dabigatran etexilate compound of the present invention measured by Karl Fischer method is 2.5% (theoretical: 2.4%); the result of thermogravimetric analysis shows that it is a monohydrate.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap